RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/565E92C8F3D3D5A96E26F8A8709A87C4B6AE114286254C660E39014952DC4542A5A5E1FEE449A7FA2E7840F4A24F879Ehttp://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/565E92C8F3D3D5A96E26F8A8709A87C4B6AE114286254C660E39014952DC4542A5A5E1FEE449A7FA2E7840F4A24F879Ehttp://www.w3.org/2000/01/rdf-schema#comment"TYMS was absent in 100% of circulating tumor cells (CTCs) from locally advanced rectal cancer patients with pathologic complete response yet was expressed in 83% of non-responders prior to surgery (S2). RAD23B was expressed in CTCs from 75% of non-responders prior to neoadjuvant chemoradiation (S1) and in 100% of non-responders at S2. 100% of non-responders expressed TYMS mRNA at both timepoints."xsd:string
http://purl.uniprot.org/uniprot/#_E6F0501B6A8D834F17E21DA0249229CEDF117D979FF9B3A9F95C2131F8FEF2E7462F73579F41AA44797EE4A07C5BFFE7http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/565E92C8F3D3D5A96E26F8A8709A87C4B6AE114286254C660E39014952DC4542A5A5E1FEE449A7FA2E7840F4A24F879E
http://purl.uniprot.org/uniprot/B7Z4W4http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/565E92C8F3D3D5A96E26F8A8709A87C4B6AE114286254C660E39014952DC4542A5A5E1FEE449A7FA2E7840F4A24F879E
http://purl.uniprot.org/uniprot/#_B7Z4W4-mappedCitation-31247977http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/565E92C8F3D3D5A96E26F8A8709A87C4B6AE114286254C660E39014952DC4542A5A5E1FEE449A7FA2E7840F4A24F879E